AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women
How to Cite
OrthoEvidence. AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women. ACE Report. 2018;7(3):34. Available from: https://myorthoevidence.com/AceReport/Report/10156
Abaloparatide Reduced the Risk of Major Nonvertebral Fractures in Postmenopausal Women with Osteoporosis
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
1645 postmenopausal women with osteoporosis were randomized with daily subcutaneous injections or either abaloparatide 80ug or placebo for 18 months. Participants were followed up for the incidence of major non-vertebral fracture over 18 months of treatment. Results demonstrated a significantly lower incidence of major non-vertebral fracture among participants who received abaloparatide compared t...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE